Merck Stock Downgraded Despite Cancer Vaccine Success

Merck's stock has been downgraded despite a significant win with its cancer vaccine, as analysts note a stretched valuation and a strong but potentially overvalued pipeline. This comes after a period of positive news for the pharmaceutical company.

20 Aug, 20:20 — 20 Aug, 20:20

Post Share

Sources

Showing 1 of 2 sources

Barron'sHigh13d ago

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win - Barron's

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win Barron's

Read full article →

Coverage Timeline

First report: Barron's · 20 Aug, 20:20|Full coverage: 2 · 18h|Window: 18h

Left-leaningCenterRight-leaning

Barron's20 Aug, 20:20First to report

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win - Barron's

18h later

investing-com21 Aug, 14:47Latest update

Merck Stock Downgraded Despite Cancer Vaccine Success

Sources

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win - Barron's

Coverage Timeline

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win - Barron's

Merck stock analysis: great pipeline at a stretched valuation

Related Stories

Uber and Wayve Launch Robotaxi Service in London

NetApp and Broadcom Shares Fall Despite Beating Earnings Estimates

DOJ Expands Beef Price Antitrust Probe to Major Retailers

Uber Announces Global Layoffs and Exits Nigerian, Ugandan Markets